KRAScendo-1: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Sponsor: Hoffmann-La Roche
Full Title
Protocol BO45217: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
Study Treatment
Divarasib, an oral KRAS G12C inhibitor
Eligibility/Info
Eligible participants will have an unresectable/metastatic non-small cell lug cancer with a KRAS G12C mutation. Participants must have previously been treated in the metastatic setting with platinum-based doublet chemotherapy as well as a PD-(L)1 inhibitor. Participants cannot have been treated with a KRAS G12C or pan-RAS inhibitor prior to enrolling in this clinical trial.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
